vs
Amphastar Pharmaceuticals, Inc.（AMPH）与PREFORMED LINE PRODUCTS CO（PLPC）财务数据对比。点击上方公司名可切换其他公司
Amphastar Pharmaceuticals, Inc.的季度营收约是PREFORMED LINE PRODUCTS CO的1.1倍（$183.1M vs $173.1M），Amphastar Pharmaceuticals, Inc.净利率更高（13.3% vs 4.9%，领先8.5%），PREFORMED LINE PRODUCTS CO同比增速更快（3.6% vs -1.8%），Amphastar Pharmaceuticals, Inc.自由现金流更多（$24.6M vs $11.8M），过去两年PREFORMED LINE PRODUCTS CO的营收复合增速更高（10.8% vs 3.2%）
安福斯制药是一家上市的美国特种制药企业，公司成立于2004年5月，核心业务为吸入制剂及鼻腔给药产品的研发、生产与销售，聚焦特色医药领域深耕发展。
预成型线路产品公司（PLPC）研发、生产和销售适用于输配电、通信及可再生能源基建领域的工程硬件组件，服务全球多地的公用事业、网络运营商及工业客户，提供可提升网络可靠性与运营效率的解决方案。
AMPH vs PLPC — 直观对比
营收规模更大
AMPH
是对方的1.1倍
$173.1M
营收增速更快
PLPC
高出5.4%
-1.8%
净利率更高
AMPH
高出8.5%
4.9%
自由现金流更多
AMPH
多$12.8M
$11.8M
两年增速更快
PLPC
近两年复合增速
3.2%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $183.1M | $173.1M |
| 净利润 | $24.4M | $8.4M |
| 毛利率 | 46.8% | 29.8% |
| 营业利润率 | 19.4% | 6.8% |
| 净利率 | 13.3% | 4.9% |
| 营收同比 | -1.8% | 3.6% |
| 净利润同比 | -35.7% | -19.3% |
| 每股收益（稀释后） | $0.51 | $1.72 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AMPHPLPC
| Q4 25 | $183.1M | $173.1M | ||
| Q3 25 | $191.8M | $178.1M | ||
| Q2 25 | $174.4M | $169.6M | ||
| Q1 25 | $170.5M | $148.5M | ||
| Q4 24 | $186.5M | $167.1M | ||
| Q3 24 | $191.2M | $147.0M | ||
| Q2 24 | $182.4M | $138.7M | ||
| Q1 24 | $171.8M | $140.9M |
净利润AMPHPLPC
| Q4 25 | $24.4M | $8.4M | ||
| Q3 25 | $17.4M | $2.6M | ||
| Q2 25 | $31.0M | $12.7M | ||
| Q1 25 | $25.3M | $11.5M | ||
| Q4 24 | $38.0M | $10.5M | ||
| Q3 24 | $40.4M | $7.7M | ||
| Q2 24 | $37.9M | $9.4M | ||
| Q1 24 | $43.2M | $9.6M |
毛利率AMPHPLPC
| Q4 25 | 46.8% | 29.8% | ||
| Q3 25 | 51.4% | 29.7% | ||
| Q2 25 | 49.6% | 32.7% | ||
| Q1 25 | 50.0% | 32.8% | ||
| Q4 24 | 46.5% | 33.3% | ||
| Q3 24 | 53.3% | 31.1% | ||
| Q2 24 | 52.2% | 31.9% | ||
| Q1 24 | 52.4% | 31.3% |
营业利润率AMPHPLPC
| Q4 25 | 19.4% | 6.8% | ||
| Q3 25 | 13.2% | 7.4% | ||
| Q2 25 | 24.2% | 10.1% | ||
| Q1 25 | 21.9% | 8.8% | ||
| Q4 24 | 24.2% | 10.5% | ||
| Q3 24 | 29.8% | 7.1% | ||
| Q2 24 | 30.3% | 8.1% | ||
| Q1 24 | 27.9% | 8.2% |
净利率AMPHPLPC
| Q4 25 | 13.3% | 4.9% | ||
| Q3 25 | 9.0% | 1.5% | ||
| Q2 25 | 17.8% | 7.5% | ||
| Q1 25 | 14.8% | 7.8% | ||
| Q4 24 | 20.4% | 6.3% | ||
| Q3 24 | 21.1% | 5.2% | ||
| Q2 24 | 20.8% | 6.8% | ||
| Q1 24 | 25.1% | 6.8% |
每股收益（稀释后）AMPHPLPC
| Q4 25 | $0.51 | $1.72 | ||
| Q3 25 | $0.37 | $0.53 | ||
| Q2 25 | $0.64 | $2.56 | ||
| Q1 25 | $0.51 | $2.33 | ||
| Q4 24 | $0.74 | $2.13 | ||
| Q3 24 | $0.78 | $1.54 | ||
| Q2 24 | $0.73 | $1.89 | ||
| Q1 24 | $0.81 | $1.94 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $282.8M | — |
| 总债务越低越好 | $608.7M | $38.3M |
| 股东权益账面价值 | $788.8M | $475.5M |
| 总资产 | $1.6B | $653.6M |
| 负债/权益比越低杠杆越低 | 0.77× | 0.08× |
8季度趋势，按日历期对齐
现金及短期投资AMPHPLPC
| Q4 25 | $282.8M | — | ||
| Q3 25 | $276.2M | — | ||
| Q2 25 | $231.8M | — | ||
| Q1 25 | $236.9M | — | ||
| Q4 24 | $221.6M | — | ||
| Q3 24 | $250.5M | — | ||
| Q2 24 | $217.8M | — | ||
| Q1 24 | $289.6M | — |
总债务AMPHPLPC
| Q4 25 | $608.7M | $38.3M | ||
| Q3 25 | $608.6M | $36.0M | ||
| Q2 25 | $607.7M | $31.8M | ||
| Q1 25 | $603.9M | $29.1M | ||
| Q4 24 | $601.6M | $20.8M | ||
| Q3 24 | $596.4M | $27.2M | ||
| Q2 24 | $586.9M | $31.6M | ||
| Q1 24 | $594.0M | $55.0M |
股东权益AMPHPLPC
| Q4 25 | $788.8M | $475.5M | ||
| Q3 25 | $776.7M | $466.3M | ||
| Q2 25 | $757.5M | $460.7M | ||
| Q1 25 | $751.3M | $435.8M | ||
| Q4 24 | $732.3M | $422.3M | ||
| Q3 24 | $727.7M | $429.0M | ||
| Q2 24 | $713.3M | $416.2M | ||
| Q1 24 | $672.4M | $413.4M |
总资产AMPHPLPC
| Q4 25 | $1.6B | $653.6M | ||
| Q3 25 | $1.7B | $644.6M | ||
| Q2 25 | $1.6B | $631.5M | ||
| Q1 25 | $1.6B | $592.5M | ||
| Q4 24 | $1.6B | $573.9M | ||
| Q3 24 | $1.5B | $592.0M | ||
| Q2 24 | $1.5B | $572.6M | ||
| Q1 24 | $1.6B | $586.1M |
负债/权益比AMPHPLPC
| Q4 25 | 0.77× | 0.08× | ||
| Q3 25 | 0.78× | 0.08× | ||
| Q2 25 | 0.80× | 0.07× | ||
| Q1 25 | 0.80× | 0.07× | ||
| Q4 24 | 0.82× | 0.05× | ||
| Q3 24 | 0.82× | 0.06× | ||
| Q2 24 | 0.82× | 0.08× | ||
| Q1 24 | 0.88× | 0.13× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $32.9M | $21.9M |
| 自由现金流经营现金流 - 资本支出 | $24.6M | $11.8M |
| 自由现金流率自由现金流/营收 | 13.4% | 6.8% |
| 资本支出强度资本支出/营收 | 4.5% | 5.9% |
| 现金转化率经营现金流/净利润 | 1.35× | 2.60× |
| 过去12个月自由现金流最近4个季度 | $121.2M | $33.3M |
8季度趋势，按日历期对齐
经营现金流AMPHPLPC
| Q4 25 | $32.9M | $21.9M | ||
| Q3 25 | $52.6M | $18.9M | ||
| Q2 25 | $35.6M | $26.9M | ||
| Q1 25 | $35.1M | $5.7M | ||
| Q4 24 | $29.0M | $24.1M | ||
| Q3 24 | $60.0M | $9.4M | ||
| Q2 24 | $69.1M | $28.3M | ||
| Q1 24 | $55.3M | $5.8M |
自由现金流AMPHPLPC
| Q4 25 | $24.6M | $11.8M | ||
| Q3 25 | $47.2M | $8.3M | ||
| Q2 25 | $25.0M | $18.6M | ||
| Q1 25 | $24.4M | $-5.3M | ||
| Q4 24 | $16.6M | $20.6M | ||
| Q3 24 | $46.2M | $5.8M | ||
| Q2 24 | $63.1M | $24.6M | ||
| Q1 24 | $46.5M | $1.8M |
自由现金流率AMPHPLPC
| Q4 25 | 13.4% | 6.8% | ||
| Q3 25 | 24.6% | 4.7% | ||
| Q2 25 | 14.3% | 10.9% | ||
| Q1 25 | 14.3% | -3.6% | ||
| Q4 24 | 8.9% | 12.3% | ||
| Q3 24 | 24.1% | 3.9% | ||
| Q2 24 | 34.6% | 17.7% | ||
| Q1 24 | 27.1% | 1.3% |
资本支出强度AMPHPLPC
| Q4 25 | 4.5% | 5.9% | ||
| Q3 25 | 2.8% | 6.0% | ||
| Q2 25 | 6.1% | 4.9% | ||
| Q1 25 | 6.3% | 7.4% | ||
| Q4 24 | 6.7% | 2.1% | ||
| Q3 24 | 7.2% | 2.4% | ||
| Q2 24 | 3.3% | 2.7% | ||
| Q1 24 | 5.1% | 2.8% |
现金转化率AMPHPLPC
| Q4 25 | 1.35× | 2.60× | ||
| Q3 25 | 3.03× | 7.21× | ||
| Q2 25 | 1.15× | 2.12× | ||
| Q1 25 | 1.39× | 0.49× | ||
| Q4 24 | 0.76× | 2.30× | ||
| Q3 24 | 1.48× | 1.22× | ||
| Q2 24 | 1.82× | 3.02× | ||
| Q1 24 | 1.28× | 0.60× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AMPH
| Other Products | $62.4M | 34% |
| Baqsimi | $46.7M | 26% |
| Primatenemist | $27.9M | 15% |
| Epinephrine | $17.1M | 9% |
| Lidocaine | $14.9M | 8% |
| Glucagon | $14.1M | 8% |
PLPC
暂无分部数据
